Diagnosing multiple sclerosis (MS) is complex due to overlapping symptoms with other conditions, often delaying definitive diagnosis for months or even years.

For that very reason, advancements in research are crucial for improving diagnostic accuracy and enabling earlier intervention, which can greatly enhance a patient’s quality of life.

In this podcast episode, sponsored by Sanofi, we sit down with Dr Jiwon Oh – a leading neurologist and Medical Director of the Barlo MS Program at St. Michael’s Hospital, University of Toronto.

Here, we discuss the intricacies of secondary progressive MS (SPMS), with Dr Oh emphasizing the need to reassess SPMS subtypes and the importance of clinical trials targeting non-relapsing SPMS patients.

“It’s a challenging and risky population to study, but these patients have the greatest unmet needs in clinical practice,” she notes.

To find out more about these challenges and the efforts from researchers such as Dr Oh to address them, listen to the full episode.

Diagnosing multiple sclerosis (MS) is complex due to overlapping symptoms with other conditions, often delaying definitive diagnosis for months or even years.
For that very reason, advancements in research are crucial for improving diagnostic accuracy and enabling earlier intervention, which can greatly enhance a patient’s quality of life.
In this podcast episode, sponsored by Sanofi, we sit down with Dr Jiwon Oh – a leading neurologist and Medical Director of the Barlo MS Program at St. Michael’s Hospital, University of Toronto.
Here, we discuss the intricacies of secondary progressive MS (SPMS), with Dr Oh emphasizing the need to reassess SPMS subtypes and the importance of clinical trials targeting non-relapsing SPMS patients.
“It’s a challenging and risky population to study, but these patients have the greatest unmet needs in clinical practice,” she notes.
To find out more about these challenges and the efforts from researchers such as Dr Oh to address them, listen to the full episode.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

In this episode, sponsored by Sanofi, we’re joined by Dr Jiwon Oh to explore the need to better understand MS, and specifically SPMS, as a disease.

Advertisement